Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96LA9

UPID:
MRGX4_HUMAN

ALTERNATIVE NAMES:
Sensory neuron-specific G-protein coupled receptor 5/6

ALTERNATIVE UPACC:
Q96LA9; Q3KNU3; Q3KNU4; Q502W0; Q8TDD6; Q8TDD7

BACKGROUND:
The protein known as Mas-related G-protein coupled receptor member X4, or MrgX4, serves a pivotal function in nociceptive neurons. It is thought to regulate nociceptor function and development, including pain sensation and modulation, with enkephalins significantly activating it.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Mas-related G-protein coupled receptor member X4 presents an exciting opportunity for the discovery of new therapeutic approaches, particularly in the realm of pain management, highlighting its potential as a target for innovative analgesic drugs.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.